Entrada Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
TRDA$5.25+11.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(In thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net Income (loss) | $65,626 | $(6,685) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 3,773 | 2,841 |
| Stock‑based compensation expense | 17,915 | 13,111 |
| Net amortization of premium (accretion of discount) on marketable securities | (10,018) | (5,779) |
| Changes in operating assets and liabilities: | ||
| Collaboration receivable | 2,198 | (5,878) |
| Prepaid expenses and other current assets | (4,437) | 8,622 |
| Right-of-use assets, operating leases | 10,370 | 11,989 |
| Other non-current assets | 2,506 | (11,563) |
| Accounts payable | 991 | (2,805) |
| Accrued expenses and other current liabilities | 1,708 | 3,812 |
| Income taxes payable | (3,357) | 4,024 |
| Deferred revenue | (119,809) | 139,976 |
| Operating lease liabilities | (9,023) | (11,862) |
| Net cash (used in) provided by operating activities | (41,557) | 139,803 |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (3,158) | (5,614) |
| Purchases of marketable securities | (437,717) | (407,207) |
| Maturities of marketable securities | 413,077 | 274,426 |
| Net cash used in investing activities | (27,798) | (138,395) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock and pre-funded warrants in registered direct offering, net of issuance costs paid | 99,608 | — |
| Proceeds from issuance of common stock in connection with the Vertex Agreement | — | 19,407 |
| Proceeds from exercise of stock options | 2,782 | 1,187 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 574 | 443 |
| Net cash provided by financing activities | 102,964 | 21,037 |
| Net increase in cash, cash equivalents and restricted cash | 33,609 | 22,445 |
| Cash, cash equivalents and restricted cash at beginning of year | 71,552 | 49,107 |
| Cash, cash equivalents and restricted cash at end of year | $105,161 | $71,552 |
| Supplemental cash flow disclosures: | ||
| Purchases of property and equipment included in accounts payable and accrued expenses | $560 | $208 |
| Right-of-use assets obtained in exchange for operating lease liabilities | $— | $77,584 |
| Right-of-use assets surrendered as part of lease modification | $— | $9,445 |
| Transfer of deposits for equipment from operating to investing cash flows | $— | $617 |
| Vesting of options early exercised subject to repurchase | $51 | $91 |
| Cash paid for income taxes | $4,622 | $14,717 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.